Kiora Pharmaceuticals Stock Net Income

KPRX Stock  USD 3.31  0.11  3.22%   
Kiora Pharmaceuticals fundamentals help investors to digest information that contributes to Kiora Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kiora Stock. The fundamental analysis module provides a way to measure Kiora Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiora Pharmaceuticals stock.
Last ReportedProjected for Next Year
Net Loss-12.5 M-13.1 M
Net Loss-12.7 M-13.4 M
Net Loss-14.8 M-15.5 M
Net Loss(23.26)(24.42)
Net Income Per E B T 1.01  1.11 
Net Income Per E B T is likely to rise to 1.11 in 2024, whereas Net Loss is likely to drop (13.1 M) in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kiora Pharmaceuticals Company Net Income Analysis

Kiora Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Kiora Pharmaceuticals Net Income

    
  (12.51 M)  
Most of Kiora Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiora Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Kiora Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Kiora Pharmaceuticals is extremely important. It helps to project a fair market value of Kiora Stock properly, considering its historical fundamentals such as Net Income. Since Kiora Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kiora Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kiora Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Kiora Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(173,661)

At this time, Kiora Pharmaceuticals' Accumulated Other Comprehensive Income is fairly stable compared to the past year.
Based on the recorded statements, Kiora Pharmaceuticals reported net income of (12.51 Million). This is 103.67% lower than that of the Biotechnology sector and 117.87% lower than that of the Health Care industry. The net income for all United States stocks is 102.19% higher than that of the company.

Kiora Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiora Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics of similar companies.
Kiora Pharmaceuticals is currently under evaluation in net income category among its peers.

Kiora Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kiora Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kiora Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

Kiora Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Kiora Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kiora Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kiora Pharmaceuticals' value.
Shares
U.s. Bancorp2024-06-30
8.0
Activest Wealth Management2024-06-30
3.0
Morgan Stanley - Brokerage Accounts2024-06-30
2.0
Jpmorgan Chase & Co2024-06-30
1.0
Captrust Financial Advisors2024-06-30
0.0
Wells Fargo & Co2024-06-30
0.0
Tower Research Capital Llc2024-06-30
0.0
Two Sigma Investments Llc2024-06-30
0.0
Virtu Financial Llc2024-06-30
0.0
Aigh Capital Management, Llc30240-09-30
255.6 K
Nantahala Capital Management, Llc2024-06-30
211.1 K

Kiora Fundamentals

About Kiora Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kiora Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.